Atea Pharmaceuticals, Inc.
AVIRHealthcare|Biotechnology|US
$4.31
+0.09 (+2.13%)
DCF Value
$1.01
Tangible Book / Share
$2.55
Cash / Share
$2.74
Clinical Trials (36)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07037277 C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV | HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic | P3 | Active | 880 | RCT, Single-blind | Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir |
| NCT07728487 Study of AT-587 in Healthy Subjects | Hepatitis E | P1 | Recruiting | 62 | RCT, Double-blind | AT-587 |
| NCT06868264 C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV | HEPATITIS C VIRUS CHRONIC INFECTION | P3 | Completed | 940 | RCT, Single-blind | Bemnifosbuvir-Ruzasvir (BEM/RZR), Sofosbuvir-Velpatasvir (SOF/VEL) |
| NCT04889040 Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19 | COVID-19 | P3 | Terminated | 216 | RCT, Double-blind | RO7496998, Placebo |
| NCT05629962 SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19 | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection), COVID-19 | P3 | Completed | 2,285 | RCT, Double-blind | Bemnifosbuvir (BEM), Placebo |
| NCT04396106 Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) in a Hospital Setting | COVID-19 | P2 | Terminated | 83 | RCT, Double-blind | AT-527, AT-527 |
| NCT04709835 Study to Evaluate the Effects of AT-527 in Non-Hospitalized Adult Patients With Mild or Moderate COVID-19 | COVID-19 | P2 | Completed | 104 | RCT, Double-blind | AT-527, Placebo |
| NCT04309734 Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects | Hepatitis C, Hepatitis C, Chronic | P1P2 | Withdrawn | — | RCT, Double-blind | AT-777, Placebo, AT-527 |
| NCT04019717 Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection | Hepatitis C, Hepatitis C, Chronic | P2 | Completed | 10 | Open-label | AT-527, Daclatasvir |
| NCT05904470 A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV | Chronic Hepatitis C Virus, Hepatitis C, Chronic | P2 | Completed | 275 | Open-label | Bemnifosbuvir, Ruzasvir |
| NCT05466240 Study of AT-752 in Patients With Dengue Infection | Dengue Fever | P2 | Terminated | 21 | RCT, Double-blind | AT-752, Placebo |
| NCT07314346 Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone | Healthy Volunteer Study | P1 | Completed | 30 | Open-label | Buprenorphine/Naloxone + BEM/RZR, Methadone +BEM/RZR |
| NCT04784000 Effect of Carbamazepine on the Pharmacokinetics (PK) of AT-527 | Healthy Volunteer Study | P1 | Completed | 20 | RCT, Open-label | Period 1: AT-527 550 mg, Period 2: carbamazepine, Period 3: AT-527 550 mg + carbamazepine, Period 3: AT-527 1100 mg + carbamazepine |
| NCT07272889 Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG) | Healthy Volunteer Study | P1 | Completed | 24 | Open-label | Ethinyl Estradioll/Levonorgestrel (EE/LNG), Bemnifosbuvir/Ruzasvir (BEM/RZR), Bemnifosbuvir/Ruzasvir (BEM/RZR) + Ethinyl Estradioll/Levonorgestrel (EE/LNG) |
| NCT06911320 Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function | Healthy Volunteer Study, Hepatic Impairment | P1 | Completed | 28 | Open-label | Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination |
| NCT06356194 Drug-drug Interaction Study of Biktarvy and Bemnifosbuvir/Ruzasvir | Healthy Volunteer Study | P1 | Completed | 28 | Open-label | Cohort 1: Days 1-7 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered. Days 8-17 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered + Biktarvy (BIK). Days 18-24 BIK, Cohort 2: Days 1-10 Biktarvy (BIK). Days 11-17 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered + Biktarvy (BIK). Days 18-24 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered. |
| NCT04865445 Drug-drug Interaction Study of Midazolam and AT-527 (R07496998) | Healthy Volunteer Study | P1 | Completed | 24 | Open-label | AT-527 550 mg + midazolam, AT-527 550 mg + midazolam |
| NCT05256732 Study of AT-527 in Healthy Subjects Under Fasting Conditions or With a Meal | Healthy Volunteer Study | P1 | Completed | 136 | RCT, Double-blind | AT-527 fasted, AT-527 fed, AT-527, AT-527 single dose |
| NCT06204679 Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir | Healthy Volunteer Study | P1 | Completed | 42 | RCT, Open-label | Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fasting conditions, Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fed conditions, Bemnifosbuvir (BEM) and Ruzasvir (RZR) as reference formulation under fasting conditions |
| NCT04722627 Study of AT-752 in Healthy Subjects | Dengue | P1 | Completed | 65 | RCT, Double-blind | AT-752, Placebo |
| NCT05905484 Study of Bemnifosbuvir on Cardiac Repolarization in Healthy Subjects | Healthy Volunteer Study | P1 | Completed | 35 | RCT, Double-blind | Bemnifosbuvir (BEM), Placebo, Moxifloxacin |
| NCT05004415 Mass Balance Study of AT-527 in Healthy Adult Male Subjects (R07496998) | Healthy Volunteer Study | P1 | Completed | 6 | Open-label | AT-527 (R07496998) |
| NCT04849299 Effect of Cyclosporine on the Pharmacokinetics (PK) of AT-527 (R07496998) | Healthy Volunteer Study | P1 | Completed | 24 | RCT, Open-label | AT-527 550 mg + cyclosporine, AT-527 550 mg + cyclosporine |
| NCT05618314 Study of AT-527 in Subjects With Normal and Impaired Renal Function | Healthy Volunteer, Renal Impairment | P1 | Completed | 36 | Open-label | AT-527, AT-527, AT-527 and Probenecid |
| NCT05731843 Drug-drug Interaction Study of Ruzasvir and Bemnifosbuvir | Healthy Volunteer Study | P1 | Completed | 32 | Open-label | Cohort 1 BEM + Ruzasvir, Cohort 2 Ruzasvir + BEM |
| NCT05724693 Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function | Healthy Volunteer, Hepatic Impairment | P1 | Completed | 39 | Open-label | Bemnifosbuvir (BEM) |
| NCT05905497 The Study of Bemnifosbuvir in Healthy Japanese Subjects | Healthy Volunteer Study | P1 | Completed | 14 | Open-label | Bemnifosbuvir (BEM) |
| NCT06921941 Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Digoxin and Rosuvastatin | Healthy Volunteer Study | P1 | Completed | 38 | RCT, Open-label | Digoxin vs Digoxin + BEM/RZR vs Digoxin + 2h BEM/RZR, Rosuvastatin vs Rosuvastatin + BEM/RZR vs Rosuvastatin + 2h BEM/RZR |
| NCT05154123 Drug-drug Interaction Study of Rosuvastatin and AT-527 (R07496998) | Healthy Volunteer Study | P1 | Completed | 29 | Open-label | Drug: AT-527 + rosuvastatin, AT-527 + rosuvastatin |
| NCT04711187 Study of AT-527 in Healthy Subjects (R07496998) | Healthy Volunteer Study | P1 | Completed | 81 | RCT, Double-blind | AT-527 Formulation 1, AT-527 Formulation 2 |
| NCT03219957 Study of AT-527 in Healthy and HCV-Infected Subjects | Chronic Hepatitis C, Hepatitis C | P1 | Completed | 88 | RCT, Double-blind | AT-527 |
| NCT05366439 Study of AT-752 in Healthy Subjects in a Dengue Human Challenge Model | Dengue | P1 | Terminated | 5 | RCT, Double-blind | AT-752, Placebo Comparator |
| NCT05137626 Drug-drug Interaction Study of Digoxin and AT-527 (R07496998) | Healthy Volunteers Study | P1 | Completed | 29 | Open-label | AT-527 + digoxin, AT-527 + digoxin |
| NCT04877769 Bronchopulmonary PK of AT-527 (R07496998) | Healthy Volunteer Study | P1 | Completed | 24 | Open-label | AT-527 |
| NCT07007806 Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir | Healthy Volunteer Study | P1 | Completed | 20 | Open-label | Treatment A-Bemnifosbuvir/Ruzasvir FDC administered fasting, Treatment B-Omeprazole 20 mg dose administered fasting, Treatment C-Bemnifosbuvir/Ruzasvir FDC administered simultaneously with 20 mg dose of Omeprazole fasting, Treatment D-Bemnifosbuvir/Ruzasvir FDC administered 0.5 hour prior to 20 mg dose of Omeprazole, Treatment E-Omeprazole 40 mg administered fasting, Treatment F-Bemnifosbuvir/Ruzasvir FDC administered 2 hours after 40 mg dose Omeprazole |
| NCT05059080 A Six-Month Follow-Up Study of Participants With Coronavirus Disease 2019 (COVID-19) Previously Enrolled in a RO7496998 (AT-527) Study | COVID-19, Long COVID | Terminated | 72 | — | — |